Update from GOV.UK for: MHRA approves zanidatamab (Ziihera) for the treatment of biliary tract cancer. Received in my inbox at 4:31 am Pac. time. First published (simultaneously) at 12:31pm, 19 February 2026 UK time per the official MHRA notice. This is how we'll first learn of our own approval.

Yep, the $12.50 ask appeared on my Fidelity Active Trader at that time. Looked real enough that I thought the dam might be about to burst, but then it disappeared after only a few seconds, and the market closed a few more seconds later.

Legal short sellers were covering the day after NWBO's financing announcement on the 26th as evidenced in my account records for Fri the 27th. As of the close on the 26th, I had 500,500 shares loaned out under Fidelity's Fully Paid Lending Program. Then sometime during the first couple of hours last Friday a total of 487,097 shares were returned to my account in separate lots as follows: 289,500 shares + 10,500 shares to one account; 27,374 shares + 9,223 shares to a second account; and 150,500 shares to a third account.

What this signals to me is that these LEGAL short sellers have gotten the message from the new NWBO financing, and have correctly concluded that the upside risk now exceeds any further downside potential.

The 487,097 shares formerly loaned and now returned to me accounted for a little over 10% of Friday's 4.6M volume. For those not familiar with lending shares to shorts, the owner of the shares gives up NO rights what-so-ever, can revoke the loan on a moment's notice, can sell his loaned shares at any time, and can exert negative pressure on the short seller if he wishes. On top of that the lender (shareholder like myself) collects a handsome interest rate, credited daily to his account.

Bright Boy, About Bios Research, I found a hedge fund with that name in Ft. Worth, founded by a Ph.D. named Aaron Fletcher. Is this the outfit you're referring to as having removed their short recommendation? Can you provide any additional insight into that? Is Fletcher's stature such that he could sway other hedgies or investors?

1958 - The best year of the collectibles! I turned 16 in 1958, and have loved that year ever since. Have owned lots of collectibles including a '63 Riviera, a '65 Jag XKE roadster, a '67 Camaro 327 4spd convertible, etc. BUT, if I was starting a new collection today, the FIRST 3 cars I'd buy would ALL be 1958's...a Corvette, a Pontiac Bonneville convertible, and an Impala hardtop. Come to think of it, that would be a terrific collection all by itself!

Too much chrome you say? Nah, if you were alive in 1958, there was no such thing as too much.

Monksdream I hope you get your book finished and published!

The new "Full View" is not even REMOTELY as user friendly and helpful as the old "Classic" view. PLEASE, PLEASE, PLEASE don't force this new DIS-improvement upon us!

The 44.2 M volume on 7/8 was apparently catalyzed by BMO Capital starting NMTR at Outperform with a $5 price target. Yesterday's volume was quite similar to the 43.9 M volume on 1/29, following the Oppenheimer Buy recommendation and a $6.00 target at the time.

For several days after 1/29, there was strong follow-up buying, which so far has not happened today, with 8.9 M traded, down $0.08 with about 2 hours to the close.

Recording today's session: On the hopeful supposition that there will be something useful said today, I plan to record today's entire session. Easy to do using the Windows 10 built-in Voice Recorder. Hopefully other listeners will record as well, so that if mgmt says something which is unclear or difficult to interpret, we can re-listen and establish EXACTLY what was said.

Thanks, I like #'s 6,9,11,20, and my own new 21.

Please add this question to the list to be voted on: "Have you had any discussions with other parties regarding either partnership or buyout? If so, what can you tell us about that?"

Has management ever projected the total $ amount of this contract, either per year, or in total? I don't see or recall that they have...would be good to know! Although this news was expected, the market reaction after one hour of trading has certainly been quiet.

Insider buying very positive...we now have 6 different insiders, including the CEO, CFO, CMO, and 3 directors, all making open market buys of at least 5,000 shs each since Dec 5, at prices ranging from $2.18 down to $1.80 on the one today. Total shs bot is 35,875, and this doesn't include the 10,000 shs bot by 2 directors on the private placement at $2.31. You've got to like it when this many insiders are putting their own money on the line.

Oppenheimer maintains Outperform, lowers target slightly to $3.00 from $3.20.

December 15, 2011
07:56 EDT AIS, BPAX
theflyonthewall.com: Antares decline on LibiGel data overdone, says Oppenheimer
After Antares' (AIS) partner, BioSante (BPAX), announced disappointing efficacy data for female sexual dysfunction treatment LibiGel, Oppenheimer thinks that the placebo effect shown in the trial will be difficult to overcome. The firm lowered its target on Antares to $3 from $3.20 but maintains an Outperform rating. :theflyonthewall.com

New detailed AIS buy recommendation at Seeking Alpha by Larry Smith, a credible source...a real analyst and former Director of Research at a real firm, Smith Barney. Three articles so far, original buy on 12/6, with two followup articles. Here's the link to the original, from which the others can be accessed: http://seekingalpha.com/article/312158-antares-pharmaceuticals-a-buy-based-on-exceptional-new-product-outlook

Thanks Ron. I see you're a busy guy over at AIS, and I'm about to post something over there which I think is new info to the board.

Oppenheimer initiates CRIS at Outperform on 12/9/2011. No price target listed at this source. Anybody see a target given?

CLSN's response to the Mangrove letter has been filed with the SEC. See this article and read down to 'UPDATE' insert-text-here

Also important to read down to the 2nd comment by Condor to understand the true story. Bottom line is that mgmt. is indeed looking out for our best interests, and certainly did nothing unusual OR improper.